178 related articles for article (PubMed ID: 33426708)
1. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Chambers NE; Coyle M; Sergio J; Lanza K; Saito C; Topping B; Clark SD; Bishop C
Eur J Neurosci; 2021 Apr; 53(8):2835-2847. PubMed ID: 33426708
[TBL] [Abstract][Full Text] [Related]
2. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
[TBL] [Abstract][Full Text] [Related]
3. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
[TBL] [Abstract][Full Text] [Related]
4. Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.
Bensaid M; Michel PP; Clark SD; Hirsch EC; François C
Exp Neurol; 2016 Jan; 275 Pt 1():209-19. PubMed ID: 26571193
[TBL] [Abstract][Full Text] [Related]
5. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
6. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
7. A non-cholinergic neuronal loss in the pedunculopontine nucleus of toxin-evoked parkinsonian rats.
Pienaar IS; van de Berg W
Exp Neurol; 2013 Oct; 248():213-23. PubMed ID: 23769975
[TBL] [Abstract][Full Text] [Related]
8. Selective cholinergic depletion of pedunculopontine tegmental nucleus aggravates freezing of gait in parkinsonian rats.
Xiao H; Li M; Cai J; Li N; Zhou M; Wen P; Xie Z; Wang Q; Chang J; Zhang W
Neurosci Lett; 2017 Oct; 659():92-98. PubMed ID: 28803956
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
10. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
11. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
12. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Soghomonian JJ
Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
[TBL] [Abstract][Full Text] [Related]
13. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
[TBL] [Abstract][Full Text] [Related]
14. Low-frequency stimulation of the pedunculopontine nucleus affects gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats.
Wen P; Li M; Xiao H; Ding R; Chen H; Chang J; Zhou M; Yang Y; Wang J; Zheng W; Zhang W
Neurosci Lett; 2015 Jul; 600():62-8. PubMed ID: 26054938
[TBL] [Abstract][Full Text] [Related]
15. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
16. The anterior and posterior pedunculopontine tegmental nucleus are involved in behavior and neuronal activity of the cuneiform and entopeduncular nuclei.
Jin X; Schwabe K; Krauss JK; Alam M
Neuroscience; 2016 May; 322():39-53. PubMed ID: 26880033
[TBL] [Abstract][Full Text] [Related]
17. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
18. Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Geng X; Wang X; Xie J; Zhang X; Wang X; Hou Y; Lei C; Li M; Han H; Yao X; Zhang Q; Wang M
Behav Brain Res; 2016 Dec; 315():1-9. PubMed ID: 27515286
[TBL] [Abstract][Full Text] [Related]
19. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
F Hernández L; Castela I; Ruiz-DeDiego I; Obeso JA; Moratalla R
Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
[TBL] [Abstract][Full Text] [Related]
20. Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Dupre KB; Cruz AV; McCoy AJ; Delaville C; Gerber CM; Eyring KW; Walters JR
Neurobiol Dis; 2016 Feb; 86():1-15. PubMed ID: 26586558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
